Vaxart (VXRT) Stock Price, News & Analysis

Company Overview

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $0.51 to $0.55
• 50-Day Range: $0.46 to $0.94
• 52-Week Range: $0.45 to $1.41
• Volume: 1.12 million shs
• Average Volume: 2.37 million shs
• Market Capitalization: $117.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Buy

Vaxart Stock Analysis - MarketRank™

Vaxart scored higher than 32% of companies evaluated by MarketBeat, and ranked 798th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Vaxart has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Vaxart has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Vaxart are expected to grow in the coming year, from ($0.39) to ($0.38) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vaxart is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vaxart is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vaxart has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.99% of the float of Vaxart has been sold short.

Short Interest Ratio / Days to Cover

Vaxart has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in Vaxart has recently increased by 17.00%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vaxart does not currently pay a dividend.

Dividend Growth

Vaxart does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.99% of the float of Vaxart has been sold short.

Short Interest Ratio / Days to Cover

Vaxart has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in Vaxart has recently increased by 17.00%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.46

News Sentiment

Vaxart has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Vaxart this week, compared to 1 article on an average week.

Search Interest

Only 4 people have searched for VXRT on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.

MarketBeat Follows

12 people have added Vaxart to their MarketBeat watchlist in the last 30 days. This is an increase of 71% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vaxart insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.60% of the stock of Vaxart is held by insiders.

Percentage Held by Institutions

Only 18.05% of the stock of Vaxart is held by institutions.

VXRT Stock Analysis - Frequently Asked Questions

How have VXRT shares performed this year?

Vaxart's stock was trading at $0.6621 at the beginning of the year. Since then, VXRT shares have decreased by 21.9% and is now trading at $0.5172.
View the best growth stocks for 2025 here.

How were Vaxart's earnings last quarter?

Vaxart, Inc. (NASDAQ:VXRT) released its earnings results on Thursday, August, 8th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by $0.12. The biotechnology company had revenue of $6.40 million for the quarter, compared to analyst estimates of $65.70 million. Vaxart had a negative net margin of 431.61% and a negative trailing twelve-month return on equity of 110.46%.

When did Vaxart's stock split?

Shares of Vaxart reverse split on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split.

Who are Vaxart's major shareholders?

Top institutional shareholders of Vaxart include Millennium Management LLC (1.31%), Geode Capital Management LLC (1.14%), Silverarc Capital Management LLC (0.47%) and Squarepoint Ops LLC (0.23%). Insiders that own company stock include W Mark Watson and Fuad Ahmad.
View institutional ownership trends.

How do I buy shares of Vaxart?

Shares of VXRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vaxart own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxart investors own include Plug Power (PLUG), Workhorse Group (WKHS), FuelCell Energy (FCEL), Fortress Biotech (FBIO), Assertio (ASRT), Ovid Therapeutics (OVID) and KALA BIO (KALA).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 3/13/2025
• Next Earnings (Estimated): 3/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VXRT
• Previous Symbol: NASDAQ:NABI
• CIK: 72444
• Web: www.vaxart.com
• Phone: (650) 550-3500
• Fax: 650-871-8580
• Employees: 120
• Year Founded: 2004

Price Target and Rating

• Average Stock Price Target: $4.00
• High Stock Price Target: $4.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +659.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-82,460,000.00
• Net Margins: -431.61%
• Pretax Margin: -430.07%
• Return on Equity: -110.46%
• Return on Assets: -62.78%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.83
• Quick Ratio: 0.83

Sales & Book Value

• Annual Sales: $20.14 million
• Price / Sales: 5.95
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.38 per share
• Price / Book: 1.39

Miscellaneous

• Outstanding Shares: 227,480,000
• Free Float: 221,566,000
• Market Cap: $119.88 million
• Optionable: Optionable
• Beta: 1.69